Filtered By:
Specialty: Hematology
Nutrition: Vitamins

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 228 results found since Jan 2013.

The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation: comment.
This article is protected by copyright. All rights reserved. PMID: 27431450 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 18, 2016 Category: Hematology Authors: Mantha S, Moll S, Hilden P, Devlin S, Rose A Tags: J Thromb Haemost Source Type: research

The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non‐valvular atrial fibrillation: comment
This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - June 30, 2016 Category: Hematology Authors: Simon Mantha, Stephan Moll, Patrick Hilden, Sean Devlin, Adam Rose Tags: Letter ‐ to the Editor Source Type: research

Quality and predictors of anticoagulant control with vitamin K antagonist for stroke prevention in atrial fibrillation.
PMID: 27307147 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 15, 2016 Category: Hematology Authors: Wilson MR, Parakramawansha R, Quinn TJ, Tait RC Tags: Thromb Haemost Source Type: research

Safety and efficacy of non-vitamin K oral anticoagulant treatment compared with warfarin in patients with non-valvular atrial fibrillation who develop acute ischemic stroke or transient ischemic attack: a multicenter prospective cohort study (daVinci study)
Abstract The safety and efficacy of non-vitamin K oral anticoagulant (NOAC) compared with warfarin in treating patients with non-valvular atrial fibrillation (NVAF) who developed acute ischemic stroke or transient ischemic attack (AIS/TIA), particularly those receiving tissue-plasminogen activator (tPA) therapy, remains unclear. Between April 2012 and December 2014, we conducted a multicenter prospective cohort study to assess the current clinical practice for treating such patients. We divided the patients into two groups according to the administration of oral anticoagulants (warfarin or NOACs) and tPA therapy. ...
Source: Journal of Thrombosis and Thrombolysis - May 19, 2016 Category: Hematology Source Type: research

Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD‐AF and treated with vitamin K antagonists
Summary Vitamin K antagonist (VKA) therapy for stroke prevention in atrial fibrillation (AF) requires monitoring of the international normalized ratio (INR). We evaluated the agreement between two INR audit parameters, frequency in range (FIR) and proportion of time in the therapeutic range (TTR), using data from a global population of patients with newly diagnosed non‐valvular AF, the Global Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIELD‐AF). Among 17 168 patients with 1‐year follow‐up data available at the time of the analysis, 8445 received VKA therapy (±antiplatelet therapy) at enrolment,...
Source: British Journal of Haematology - April 11, 2016 Category: Hematology Authors: David A. Fitzmaurice, Gabriele Accetta, Sylvia Haas, Gloria Kayani, Hector Lucas Luciardi, Frank Misselwitz, Karen Pieper, Hugo Cate, Alexander G. G. Turpie, Ajay K. Kakkar, Tags: Research Paper Source Type: research

Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD ‐AF and treated with vitamin K antagonists
Summary Vitamin K antagonist (VKA) therapy for stroke prevention in atrial fibrillation (AF) requires monitoring of the international normalized ratio (INR). We evaluated the agreement between two INR audit parameters, frequency in range (FIR) and proportion of time in the therapeutic range (TTR), using data from a global population of patients with newly diagnosed non‐valvular AF, the Global Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIELD‐AF). Among 17 168 patients with 1‐year follow‐up data available at the time of the analysis, 8445 received VKA therapy (±antiplatelet therapy) at enrolment,...
Source: British Journal of Haematology - April 11, 2016 Category: Hematology Authors: David A. Fitzmaurice, Gabriele Accetta, Sylvia Haas, Gloria Kayani, Hector Lucas Luciardi, Frank Misselwitz, Karen Pieper, Hugo Cate, Alexander G. G. Turpie, Ajay K. Kakkar, Tags: Research Paper Source Type: research

Impact of point‐of‐care international normalized ratio monitoring on quality of treatment with vitamin K antagonists in non‐self‐monitoring patients: a cohort study
ConclusionsAlthough associated with lower TTR, POC INR monitoring is a safe and effective alternative to laboratory INR monitoring in NSM patients on VKA.
Source: Journal of Thrombosis and Haemostasis - March 29, 2016 Category: Hematology Authors: J. S. Biedermann, N. Rein, A. M. H. P. Besselaar, P. N. Buhre, M. P. M. Maat, F. J. M. Meer, F. W. G. Leebeek, M. J. H. A. Kruip Tags: Original Article Source Type: research

Use of the Direct Oral Anticoagulants in Obese Patients: guidance from the SSC of the ISTH
This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - February 29, 2016 Category: Hematology Authors: K Martin, J Beyer‐Westendorf, BL Davidson, MV Huisman, PM Sandset, S Moll Tags: Recommendations and Guidelines Source Type: research

VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance
Warfarin is the most commonly prescribed anticoagulant drug; however, a narrow therapeutic range and a high risk of bleeding or stroke complicate its clinical use. Warfarin resistance was defined as prolonged warfarin requirements of more than 15 mg/day to achieve therapeutic anticoagulation or failure to achieve therapeutic anticoagulation with more than 20 mg/day. The resistance is associated with polymorphisms of the vitamin K epoxide reductase-oxidase complex (VKORC1) and cytochrome P450-2C9 (CYP2C9) genes, which affect warfarin pharmacodynamics and pharmacokinetics, respectively. Identification of the VKORC1 −16...
Source: Blood Coagulation and Fibrinolysis - February 2, 2016 Category: Hematology Tags: Original Articles Source Type: research

Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants?
Abstract Over the past several years, non-vitamin K oral anticoagulants (NOACs) have been introduced into clinical practice for the treatment of venous thromboembolism and prevention of stroke in patients with nonvalvular atrial fibrillation. Clinical trials have shown these agents to have similar or less risk of major bleeding as compared to warfarin therapy. Moreover, when patients do experience a major bleeding event administration of advanced factor products is rare, and post-bleed outcomes are similar in those receiving a NOAC compared to those receiving warfarin. However, there are situations where urgent r...
Source: Journal of Thrombosis and Thrombolysis - February 1, 2016 Category: Hematology Source Type: research

Decision-making about the use of non-vitamin K oral anticoagulant therapies for patients with atrial fibrillation
Abstract Until recently, vitamin K antagonists, warfarin being the most commonly used agent in the United States, have been the only oral anticoagulant therapies available to prevent stroke in patients with atrial fibrillation (AF). In the last 5 years four new, non-vitamin K oral anticoagulants, the so-called NOACs or novel oral anticoagulants, have come to market and been approved by the Federal Drug Administration. Despite comparable if not superior efficacy in preventing AF-related stroke, and generally lower risks of major hemorrhage, particularly intracranial bleeding, the uptake of these agents has been s...
Source: Journal of Thrombosis and Thrombolysis - February 1, 2016 Category: Hematology Source Type: research

Impact of point-of-care INR monitoring on quality of treatment with vitamin K antagonists in non-self-monitoring patients: a cohort study.
CONCLUSIONS: Although associated with lower TTR, point-of-care INR monitoring is a safe and effective alternative to laboratory INR monitoring in non-self-monitoring patients on vitamin K antagonists. This article is protected by copyright. All rights reserved. PMID: 26806724 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 25, 2016 Category: Hematology Authors: Biedermann JS, van Rein N, van den Besselaar AM, Buhre PN, de Maat MP, van der Meer FJ, Leebeek FW, Kruip MJ Tags: J Thromb Haemost Source Type: research

Impact of point‐of‐care INR monitoring on quality of treatment with vitamin K antagonists in non‐self‐monitoring patients: a cohort study
ConclusionsAlthough associated with lower TTR, point‐of‐care INR monitoring is a safe and effective alternative to laboratory INR monitoring in non‐self‐monitoring patients on vitamin K antagonists.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - January 25, 2016 Category: Hematology Authors: Joseph S. Biedermann, Nienke Rein, Antonius M.H.P. van den Besselaar, Peter N. Buhre, Moniek P.M. de Maat, Felix J.M. van der Meer, Frank W.G. Leebeek, Marieke J.H.A. Kruip Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research

Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
Abstract The effectiveness and safety of rivaroxaban for stroke prevention in atrial fibrillation (SPAF) demonstrated in ROCKET AF needs to be confirmed in daily care. To evaluate effectiveness and safety of rivaroxaban therapy in SPAF patients in daily care, we used data from an ongoing, prospective, non-interventional registry of more than 2700 patients on novel oral anticoagulants in daily care. Between October 1, 2011 and February 28, 2013, a total of 1204 SPAF patients receiving rivaroxaban were enrolled. During a mean follow-up of 796.2 ± 207.3 days, the combined endpoint of stroke/transient ischaemic attac...
Source: Thrombosis and Haemostasis - January 21, 2016 Category: Hematology Authors: Hecker J, Marten S, Keller L, Helmert S, Michalski F, Werth S, Sahin K, Tittl L, Beyer-Westendorf J Tags: Thromb Haemost Source Type: research

When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH
This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - December 15, 2015 Category: Hematology Authors: Jerrold H Levy, Walter Ageno, Noel C Chan, Mark Crowther, Peter Verhamme, Jeffrey I Weitz, Tags: Recommendations and Guidelines Source Type: research